Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of Alberta
$60,000.00
Regulation of CD8+ T cell mediated anti-tumor immunity by insulin signalling
FY 2021-22
Summary
During obesity, excessive inflammation can impair the body's responsiveness to insulin, a term called insulin resistance. We discovered that immune cells are responsive to insulin, but can become insulin resistant in obese animals. Since obese individuals present with elevated risks of developing certain types of tumors, including colorectal cancer, we set out to study how the immune cells are altered during obesity and whether such alterations play a role in tumor progression. CD8+ T cells are a subset of immune cells specialized in killing tumor cells. However, CD8+ T cells are rendered less effective at doing so within the tumor microenvironment, as they may be outcompeted by metabolically active tumor cells for necessary nutrients and resources. Obesity is thought to further stiffen such competition, although how it does so is not well understood. Since obesity induces insulin resistance in CD8+ T cells, we ask whether insulin resistance intrinsic to CD8+ T cells could explain the defective anti-tumor immunity seen in obese animals and individuals. We combine diet, genetic and tumor models to study the impact of insulin receptor signalling in CD8+ T cells within and outside the tumor microenvironment. Specifically, we will examine the role insulin receptor plays in regulating CD8+ T cells' ability to travel to and eliminate tumors. We propose that obesity rewires the metabolic pathways regulated by insulin, and in doing so causes impairments to anti-tumor immunity.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
468084
Name
Tsai Sue Y
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Regulation of CD8+ T cell mediated anti-tumor immunity by insulin signalling
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Colorectal Cancer; Environmental Causes Of Cancer (Including Viruses); Immunotherapy
Abstract
During obesity, excessive inflammation can impair the body's responsiveness to insulin, a term called insulin resistance. We discovered that immune cells are responsive to insulin, but can become insulin resistant in obese animals. Since obese individuals present with elevated risks of developing certain types of tumors, including colorectal cancer, we set out to study how the immune cells are altered during obesity and whether such alterations play a role in tumor progression. CD8+ T cells are a subset of immune cells specialized in killing tumor cells. However, CD8+ T cells are rendered less effective at doing so within the tumor microenvironment, as they may be outcompeted by metabolically active tumor cells for necessary nutrients and resources. Obesity is thought to further stiffen such competition, although how it does so is not well understood. Since obesity induces insulin resistance in CD8+ T cells, we ask whether insulin resistance intrinsic to CD8+ T cells could explain the defective anti-tumor immunity seen in obese animals and individuals. We combine diet, genetic and tumor models to study the impact of insulin receptor signalling in CD8+ T cells within and outside the tumor microenvironment. Specifically, we will examine the role insulin receptor plays in regulating CD8+ T cells' ability to travel to and eliminate tumors. We propose that obesity rewires the metabolic pathways regulated by insulin, and in doing so causes impairments to anti-tumor immunity.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tsai, Sue Y
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $60,000~ $0~